oral selective PI3K_ kinase inhibitor

<10 mg proj. human dose

from virtual screening and opt.

ACS Med. Chem. Lett., Nov. 19, 2020

Merck, Boston, CA

Structure of compound 4d

“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: